ArticleCirculation research2025
Macrophage-Derived CCL24 Promotes Cardiac Fibrosis Via Fibroblast CCR3.
Article in Circulation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Macrophage heterogeneity in organ fibrosis in the era of single-cell omics.Molecular biology reports · 2026Review
- Macrophage-Derived Extracellular Vesicles Deliver Progranulin to Alleviate Skin Wound Fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Macrophage regulation of extracellular matrix remodeling in aging skeletal muscle.Ageing research reviews · 2026Review
- Non-reproductive tumor progression impairs ovarian function through CXCL10-IL18R1 axis.Experimental & molecular medicine · 2026Article
- Review
- Ginsenoside Rg1 Ameliorates the Learning and Memory Deficits of 5xFAD Mice by Inhibiting CCR3 Activity: Insights from In Vivo and In Vitro Investigations.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Synergistic Activation of Immunogenic Cell Death and the cGAS-STING Pathway by Engineered Zinc/Manganese-Based Metal-Organic Framework Nanoplatforms for Colon Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Sequential exposure to histological chorioamnionitis and postnatal hyperoxia alters gene expression in cord blood monocytes.Frontiers in pediatrics · 2026Article
- Immunometabolic regulation of cardiac macrophages in heart failure with preserved ejection fraction.Frontiers in immunology · 2026Review
- Immune Cell-Mediated Inflammation in Heart Failure: Subset Heterogeneity and Targeted Therapy.International journal of general medicine · 2026Review
- c-Myc: an emerging participant in heart failure.Frontiers in cardiovascular medicine · 2026Review
- NAMPT orchestrates fibroblast cuproptosis and immune crosstalk during IPF progression.Frontiers in immunology · 2026Article
- When Resident Macrophages Call, Fibroblasts Answer: CCL24-CCR3 in Fibrosis.Circulation research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Funding
Abstract
backgroundInflammation is a significant risk factor and contributor to the development of cardiovascular disease by driving adaptive and maladaptive responses to cardiac injury. Macrophages are the most abundant immune cells in the heart and play an important role in the remodeling of cardiac tissue. Cardiac resident macrophages (CRMs) are integral components of the myocardium, where they have key roles in inflammation, tissue injury, and remodeling. However, the precise mechanisms by which CRMs regulate remodeling in heart failure remain poorly understood.
methodsWe used in vivo and ex vivo approaches to show that CRMs are the primary source of the chemokine CCL24 (C-C motif chemokine ligand 24) in the heart. To investigate the role of CCL24 on cardiac function following pressure overload, we subjected CCL24-deficient mice to transverse aortic constriction. To determine the role of its receptor CCR3 (C-C chemokine receptor type 3) in fibroblast activation, we used CRISPR (clustered regularly interspaced short palindromic repeats) and Cas9 (CRISPR-associated protein 9) to generate fibroblast-specific CCR3-deficient mice. We used cardiac fibroblasts to determine the direct effects of CCL24 and the signaling pathways downstream of CCR3 required for their activation and proliferation.
resultsWe identified a subpopulation of CRMs that expresses high levels of CCL24 during pressure overload-induced injury. Following transverse aortic constriction, CCL24 deficiency ameliorated cardiac fibrosis, suggesting a pathological role for CCL24 and revealing that CRMs are a heterogeneous population with dichotomous roles in mediating cardiac remodeling. Mechanistically, CCL24 directly activated cardiac fibroblasts through its sole receptor, CCR3, in an inflammation-independent process. The engagement of the CCR3 receptor promoted fibroblast proliferation and activation via PI3K (phosphoinositide 3-kinase) and the release of the key fibrotic cytokine TGF (transforming growth factor)-β. Following pressure overload, fibroblast-specific deletion of CCR3 improved cardiac function and reduced fibrosis to a degree comparable to that observed in CCL24-deficient mice. Notably, administration of a CCL24-blocking antibody or a CCR3 antagonist enhanced cardiac function in pressure-overloaded mice, underscoring the CCL24-CCR3 axis as a promising therapeutic target for heart failure.
conclusionsMacrophage-derived CCL24 aggravates fibrosis via the CCR3 receptor, impairing cardiac function in heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.